Eli Lilly | LLY - Beban Penjualan Dan Administrasi





Beban Penjualan Dan Administrasi Perubahan Tanggal
AbbVie USD 3.63B 54M 2026-06
Abbott USD 4.27B 669M 2026-09
ALKERMES USD 196.64M 67.96M 2026-06
Amgen USD 1.72B 134M 2026-06
AstraZeneca USD 5.8B 735M 2026-06
Baxter International USD 730M 5M 2026-09
Biogen USD 752M 42.3M 2026-09
Bristol-Myers Squibb USD 1.7B 127M 2026-09
Coherus Biosciences USD 15M 6.26M 2025-12
Drreddys Laboratories INR 14.47B 12.45B 2026-03
Eli Lilly USD 3.12B 305M 2026-09
Gilead Sciences USD 1.52B 70M 2026-06
GlaxoSmithKline GBP 2.16B 39M 2026-09
Glaxosmithkline GBP 2.12B 1.44B 2026-03
J&J USD 6.25B 168M 2026-09
Medtronic 3.2B 141M 2026-06
Merck USD 2.86B 25M 2026-09
Neurocrine Biosciences USD 383.1M 64.6M 2026-06
Novartis USD 3.24B 101M 2026-06
Novartis USD 3.14B 296M 2026-03
Novo Nordisk DKK 16.31B 3.09B 2026-06
Perrigo USD 3.28B 3.02B 2026-06
Pfizer USD 3.41B 496M 2026-06
Phibro Animal Health USD 78.32M 10.24M 2025-12
Prestige Brands USD 43.3M 13.02M 2026-06
Regeneron Pharmaceuticals USD 662.1M 14.4M 2026-06
Roche Holding CHF 6.37B 908M 2026-06
Sanofi EUR 2.63B 307M 2026-06
Sanofi EUR 2.49B 252M 2026-03
United Therapeutics USD 206.7M 50.1M 2026-06
Zoetis USD 592M 4M 2026-06